Market Overview - The total trading volume in the Shanghai and Shenzhen markets reached 2.89 trillion yuan, a decrease of 353.3 billion yuan compared to the previous trading day [4]. - On January 27, all three major A-share indices closed higher, with the Shanghai Composite Index rising by 0.18%, the Shenzhen Component Index by 0.09%, and the ChiNext Index by 0.71% [1]. Sector Performance - The semiconductor sector showed significant strength, with stocks like Dongxin Technology and Shengke Communication hitting the daily limit, both up by 20% [3]. - The AI computing industry chain also performed well, alongside gains in the storage and CPO sectors [2]. - Conversely, the coal, pharmaceutical retail, and commercial sectors experienced notable declines [2]. Individual Stock Movements - Notable gainers included Dongxin Technology (+20.00% to 153.23 yuan) and Shengke Communication (+20.00% to 162.53 yuan) [3]. - In the pharmaceutical sector, stocks such as Shuyuan Pingmin and Dajia Weikang saw declines exceeding 8% [4]. Fund Flow - Main funds saw a net inflow into sectors such as electronics, communications, machinery, defense, and non-ferrous metals, while experiencing net outflows from power equipment, non-bank financials, pharmaceuticals, food and beverage, and public utilities [6]. - Specific stocks with significant net inflows included Zhongji Xuchuang (34.13 billion yuan), Tianfu Communication (20.88 billion yuan), and Dongxin Technology (20.05 billion yuan) [7]. - Conversely, stocks like Ningde Times, Kweichow Moutai, and Cambrian Technologies faced net outflows of 10.11 billion yuan, 9.65 billion yuan, and 8.95 billion yuan, respectively [8]. Analyst Insights - Huaxi Securities suggests that the "slow bull" trend in A-shares is likely to continue [10]. - CITIC Securities expresses a clear outlook on the AI industry trend, maintaining a positive view on the optical communication sector [10]. - Huatai Securities indicates that oil prices may have entered a phase of bottoming and rebound [10].

Core Viewpoint - The joint issuance of the "Opinions on Promoting High-Quality Development of the Pharmaceutical Retail Industry" by nine departments aims to enhance the industry through 18 measures focusing on mergers and acquisitions, service transformation, and regulatory optimization [1] Group 1: Industry Impact - The "Opinions" are expected to accelerate the outflow of hospital prescriptions, contributing to growth in the pharmaceutical retail sector [1] - The document encourages horizontal mergers and acquisitions among retail pharmaceutical companies, aiming to optimize the business environment and streamline the licensing process for integrated stores [1][2] - The number of pharmacies in China is projected to decline, with a total of 686,426 stores by the end of Q3 2025, marking a reduction of nearly 20,000 stores since Q4 2024 [2] Group 2: Market Opportunities - The rapid exit of small and medium-sized pharmacies creates market opportunities for leading companies to consolidate and expand their market share through mergers and acquisitions [2] - The "Opinions" promote the transformation of pharmacies from mere sales points to health service hubs, providing new growth avenues for listed pharmacies facing revenue stagnation [2] Group 3: Compliance and Management - Regulatory changes are pushing for a shift towards digital and preventive oversight, enhancing compliance advantages for listed pharmacies compared to smaller competitors [3] - Companies like Yifeng Pharmacy have demonstrated significant profit growth through refined management and compliance, with a 10.27% increase in net profit year-on-year for the first three quarters of 2025 [3] - The core competitiveness of retail pharmacies is increasingly seen in their professional capabilities, with companies developing comprehensive pharmaceutical service systems [3][4]

Core Viewpoint - The A-share market for pharmaceutical retail stocks experienced a collective rise, driven by new government measures aimed at enhancing pharmaceutical services and encouraging retail drug sales [1] Group 1: Market Performance - Pharmaceutical retail stocks such as Renmin Tongtai and Yifeng Pharmacy hit the daily limit up, while Luyuan Pharmaceutical rose over 7%, Daclin increased over 6%, and Jiuzhoutong gained over 5% [1] - Other notable performers included Zhongyao Holdings, Yaoyigou, Haiwang Biological, Hefuchina, and Shuyupingmin, all rising over 4% [1] Group 2: Government Measures - The Ministry of Commerce and nine other departments issued a document proposing improvements in pharmaceutical services, enhancing pharmacy service capabilities, and promoting prescription circulation to improve the purchasing experience [1] - Measures include optimizing outpatient service coordination for designated retail pharmacies and encouraging retail drug companies to participate in centralized drug procurement [1] - The government is promoting horizontal mergers and acquisitions among retail drug companies and encouraging the sale of innovative drugs and reference preparations through retail channels [1] - There is an emphasis on encouraging e-pharmacy platforms to open data interfaces and strengthen the monitoring of price linkages between online and offline drug retail prices and provincial procurement platform prices [1]

Group 1 - The core viewpoint of the article highlights a collective rise in A-share pharmaceutical commercial stocks, driven by government initiatives to enhance pharmaceutical services and retail drug sales [1] - The Ministry of Commerce and nine other departments issued a document proposing measures to improve pharmaceutical services, enhance pharmacy service capabilities, and promote prescription circulation to improve the purchasing experience [1] - The document encourages pharmaceutical retail companies to engage in horizontal mergers and acquisitions, and to innovate in drug sales channels, including the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2 - Notable stock performances include: - Renmin Tongtai (人民同泰) with a rise of 10.04% and a total market value of 72.43 billion [2] - Yifeng Pharmacy (益丰药房) increasing by 10.02% with a market cap of 301 billion [2] - Luyuan Pharmaceutical (鹭燕医药) up by 7.76% with a market value of 70.13 billion [2] - Dacelin (大参林) rising by 6.63% with a market cap of 242 billion [2] - Jiuzhoutong (九州通) increasing by 5.27% with a market value of 282 billion [2] - Other companies showing significant gains include Zhongyao Holdings (重药控股) up by 4.89%, Yaoyigou (药易购) up by 4.42%, and Haiwang Biological (海王生物) up by 4.41% [2]

Group 1 - The company, Shuyu Pingmin, announced that its fourth board meeting for the year 2026 was held on January 20, 2026, combining in-person and remote voting methods [1] - The meeting reviewed proposals regarding the application for comprehensive credit limits and guarantees from banks and other institutions for the year 2026 [1]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2026-006 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于2026年1月20日召开第四届 董事会第十六次会议，审议通过了《关于提请召开公司2026年第一次临时股东会的议案》， 决定于2026年2月5日（星期四）14:45以现场表决与网络投票相结合的方式召开公司2026年 第一次临时股东会，现将本次股东会的有关事项公告如下： 一、召开会议的基本情况 1、会议届次：2026年第一次临时股东会 2、会议的召集人：董事会 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和国公司法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的 有关规 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2026-004 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 1、审议通过《关于 2026 年度公司及子公司向银行等机构申请综合授信额度及提供担 保的议案》 董事会 同意 2026 年度公 司及子公司 拟向银行等 机构申请总额 不超过人民币 687,080.00 万元的综合授信，同时公司及子公司预计为上述综合授信额度提供不超过人民 币 145,412.17 万元的担保。授信额度及担保额度有效期自审议本议案的 2026 年第一次临 时股东会审议通过之日起十二个月。 具体授信金额、授信期限等以银行等机构实际审批为准，授信额度在授权期限内可循 环滚动使用。本次担保额度为公司及子公司对公司合并报表范围内各级子公司 2026 年度预 计发生的担保额度，其中，公司向控股子公司福州榕参医药连锁有限公司、山东漱玉康杰 药业有限公司提供全额担保；公司向其他控股子公司按照持股比例提供担保，控股子公司 其他股东将提供同比例担保。本次被担保对象为公司合并报表范围内各级子公司，经营情 况稳定，资信状况良好，公司 ...

Core Viewpoint - The announcement indicates that the controlling shareholder, Li Wenjie, has released a portion of his pledged shares, which will not affect the company's control or have a substantial impact on its operations [1] Group 1: Share Pledge Details - Li Wenjie has released 10 million shares from pledge, accounting for 7.43% of his total holdings and 2.47% of the company's total share capital [1] - The release of the pledge started on November 21, 2023, and will end on January 19, 2026 [1] - The pledgee is Huaneng Guicheng Trust Co., Ltd [1] Group 2: Current Pledge Status - As of the announcement date, Li Wenjie and his concerted parties have a total of 44.21 million shares pledged, which represents 20.94% of his holdings and 10.90% of the company's total share capital [1] - The release of the pledge will not lead to a change in control [1]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2026-007 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 一、控股股东股份解除质押基本情况 | 股东 名称 | 是否为控股 股东或第一 | 本次解除质 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一致行动人 | 押数量（股） | 比例（%） | 比例（%） | | | | | 李文杰 | 是 | 10,000,000 | 7.43 | 2.47 | 2023 年 11 | 2026 年 1 月 | 华能贵诚信托有限 | | | | | | | 月 21 日 | 19 日 | 公司 | | 合计 | — | 10,000,000 | 7.43 | 2.47 | — | — | — | （一）本次解除质押基本情况 截至 2026 年 1 月 19 日， ...

| | | 漱玉平民大药房连锁股份有限公司 关于 2026 年度公司及子公司向银行等机构 申请综合授信额度及提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2026 年 1 月 20 日召开第四 届董事会第十六次会议，以 9 票同意、0 票反对、0 票弃权审议通过了《关于 2026 年度公 司及子公司向银行等机构申请综合授信额度及提供担保的议案》，该议案尚需提交公司股东 会审议。现将相关事项公告如下： 一、综合授信额度及担保情况概述 根据公司经营发展的需要，2026 年度公司及子公司拟向银行等机构申请总额不超过人 民币 687,080.00 万元的综合授信，同时公司及子公司预计为上述综合授信额度提供不超过 人民币 145,412.17 万元的担保。授信额度及担保额度有效期自审议本议案的 2026 年第一 次临时股东会审议通过之日起十二个月。 上述综合授信形式及用途包括但不限于贷款、国内贸易融资业务、银行承兑汇票、商 票保贴、商票贴现、国内保理、国内信用证、融资性理财、中票、短融、超短融、保 ...